GLP1R and metabolic dysfunction-associated steatotic liver disease: Our recent animal study with semaglutide confirmed the lack of GLP-1R expression in the liver, and indicated the mechanism for improving NAFLD/NASH to be indirect, via reduced inflammation (111).